BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 30613964)

  • 21. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Li WF; Chen L; Sun Y; Ma J
    Chin J Cancer; 2016 Nov; 35(1):94. PubMed ID: 27846913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
    Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
    Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
    Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
    Fangzheng W; Chuner J; Lei W; Fengqin Y; Zhimin Y; Quanquan S; Tongxin L; Min X; Peng W; Bin L; Aizawa R; Sakamoto M; Zhenfu F
    Oncotarget; 2017 Oct; 8(53):91150-91161. PubMed ID: 29207632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Huang PY; Cao KJ; Guo X; Mo HY; Guo L; Xiang YQ; Deng MQ; Qiu F; Cao SM; Guo Y; Zhang L; Li NW; Sun R; Chen QY; Luo DH; Hua YJ; Mai HQ; Hong MH
    Oral Oncol; 2012 Oct; 48(10):1038-1044. PubMed ID: 22591726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Huang PY; Mai HQ; Luo DH; Qiu F; Li NW; Xiang YQ; Chen QY; Zhang L; Sun R; Cao KJ; Guo L; Deng MQ; Mo HY; Guo X; Zhang F; Cao SM; Chen MY; Guo Y; Fan YY; Hu W; Hua YJ; Xie GF; Hong MH
    Ai Zheng; 2009 Oct; 28(10):1033-42. PubMed ID: 19799810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio.
    Ng WT; Tung SY; Lee V; Ngan RKC; Choi HCW; Chan LLK; Leung TW; Siu LL; Lu TX; Tan T; Tan EH; Sze HCK; Ng AWY; Yiu HHY; O'Sullivan B; Chappell R; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1078-1086. PubMed ID: 29885997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
    Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
    Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
    Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
    Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
    Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
    BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.